Pfizer's Omicron specific vaccine to be ready by March, says CEO
Pfizer's vaccine that specifically targets the Omicron variant of Covid-19 will be ready in March, the pharmaceutical giant's CEO Albert Bourla has said11-01-2022
11-01-2022
US CDC recommends Pfizer's Covid vaccine booster dose for ages 12 to 15
The US's CDC said it expanded the eligibility of Pfizer Inc and BioNTech SE's booster doses to those 12 to 15 years old06-01-2022
US FDA authorises Pfizer-BioNTech booster shots for kids aged 12-15
The US FDA has expanded the emergency use authorisation for the Pfizer-BioNTech Covid-19 vaccine boosters to children aged 12 to 15.04-01-2022
PFIZER LTD. - 500680 - Closure of Trading Window
We would like to inform you that, for the purpose of declaration of unaudited financial results of the Company, for the quarter ended December 31, 2021, the trading window of the Company shall remain closed from Friday, December 31, 2021 (close of business) till 48 hours after the results are made public. We request you to kindly take the above on record.31-12-2021
Moderna slump hits 50% from peak, erasing $98 billion value
Moderna's shares were pressured as coronavirus pills by Pfizer and Merck & Co recently received FDA authorisation30-12-2021
South Korea approves emergency authorisation of Pfizer's oral Covid pill
South Korea on Monday approved an emergency authorization of US drug giant Pfizer Inc.'s oral drug to treat Covid-19, making it the first such pill to be used in the country.27-12-2021
Explained: New easy-to-use Covid treatment pills come with a catch
Newly infected COVID-19 patients have two new treatment options that can be taken at home. But that convenience comes with a catch: The pills have to be taken as soon as possible once symptoms appear. The challenge is getting tested, getting a prescription and starting the pills in a short window. U.S. regulators authorized Pfizer's pill, Paxlovid, and Merck's molnupiravir last week. In high-risk patients, both were shown to reduce the chances of hospitalization or death from COVID-19, although Pfizer's was much more effective. A closer look: WHO SHOULD TAKE THESE PILLS? The antiviral pills aren't for everyone who gets a positive test. The pills are intended for those with mild or moderate COVID-19 who are more likely to become seriously ill. That includes older people and those with other health conditions like heart disease, cancer or diabetes that make them more vulnerable. Both pills were OK'd for adults while Paxlovid is authorized for children ages 12 and older. WHO SHOULD26-12-2021
US donates 5 million doses of Pfizer coronavirus vaccine to Pakistan
The United States has announced shipping an additional five million doses of Pfizer's coronavirus vaccine to Pakistan through the COVAX facility.26-12-2021
Explained: What Covid-19 pandemic therapies are available in US?
The U.S. recently added two new weapons to its small arsenal against the coronavirus: pills that patients can take at home to treat COVID-19. The drugs from Pfizer and Merck join a handful of other therapies that have been shown to blunt the worst effects of the virus. But each treatment has different advantages and tends to work best for certain types of patients at different stages of the disease. Here's a look at the current COVID-19 drugs and how they are used: PILLS The prescription pills are the first COVID-19 therapies that don't require infusions or injections delivered by health professionals. The Food and Drug Administration authorized Pfizer's Paxlovid on Wednesday and Merck's molnupiravir on Thursday. Merck's drug is for adults with a positive COVID-19 test, early symptoms and who face the highest risks of hospitalization. Pfizer's is for anyone 12 and older who likewise face the highest risks of hospitalization. Pfizer's drug is likely to become the first-choice tre25-12-2021
Pfizer's Covid pill will take about 6-8 months to come to US markets
While the US FDA has approved Pfizer antiviral pill to treat Covid-19, the White House has warned that the drug will not be available in the markets before six-eight months.24-12-2021